Summary | |
---|---|
Symbol | PEAR1 |
Name | platelet endothelial aggregation receptor 1 |
Aliases | JEDI; FLJ00193; MEGF12; multiple EGF-like-domains 12; hPEAR1; multiple EGF-like domains protein 12; multiple ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass membrane protein Note=Detected on the cell surface in resting platelets. |
Domain |
PF00053 Laminin EGF domain |
Function |
When overexpressed, reduces the number of both early and late non-adherent myeloid progenitor cells. |
Biological Process |
GO:0006909 phagocytosis GO:0006910 phagocytosis, recognition GO:0007219 Notch signaling pathway GO:0008037 cell recognition GO:0008593 regulation of Notch signaling pathway GO:0043277 apoptotic cell clearance GO:0043654 recognition of apoptotic cell GO:0045746 negative regulation of Notch signaling pathway |
Molecular Function | - |
Cellular Component |
GO:0001891 phagocytic cup |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | PEAR1 |
Name | platelet endothelial aggregation receptor 1 |
Aliases | JEDI; FLJ00193; MEGF12; multiple EGF-like-domains 12; hPEAR1; multiple EGF-like domains protein 12; multiple ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between PEAR1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | PEAR1 |
Name | platelet endothelial aggregation receptor 1 |
Aliases | JEDI; FLJ00193; MEGF12; multiple EGF-like-domains 12; hPEAR1; multiple EGF-like domains protein 12; multiple ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of PEAR1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | PEAR1 |
Name | platelet endothelial aggregation receptor 1 |
Aliases | JEDI; FLJ00193; MEGF12; multiple EGF-like-domains 12; hPEAR1; multiple EGF-like domains protein 12; multiple ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of PEAR1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of PEAR1 in various data sets.
|
Summary | |
---|---|
Symbol | PEAR1 |
Name | platelet endothelial aggregation receptor 1 |
Aliases | JEDI; FLJ00193; MEGF12; multiple EGF-like-domains 12; hPEAR1; multiple EGF-like domains protein 12; multiple ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PEAR1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | PEAR1 |
Name | platelet endothelial aggregation receptor 1 |
Aliases | JEDI; FLJ00193; MEGF12; multiple EGF-like-domains 12; hPEAR1; multiple EGF-like domains protein 12; multiple ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PEAR1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PEAR1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | PEAR1 |
Name | platelet endothelial aggregation receptor 1 |
Aliases | JEDI; FLJ00193; MEGF12; multiple EGF-like-domains 12; hPEAR1; multiple EGF-like domains protein 12; multiple ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PEAR1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | PEAR1 |
Name | platelet endothelial aggregation receptor 1 |
Aliases | JEDI; FLJ00193; MEGF12; multiple EGF-like-domains 12; hPEAR1; multiple EGF-like domains protein 12; multiple ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of PEAR1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | PEAR1 |
Name | platelet endothelial aggregation receptor 1 |
Aliases | JEDI; FLJ00193; MEGF12; multiple EGF-like-domains 12; hPEAR1; multiple EGF-like domains protein 12; multiple ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between PEAR1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | PEAR1 |
Name | platelet endothelial aggregation receptor 1 |
Aliases | JEDI; FLJ00193; MEGF12; multiple EGF-like-domains 12; hPEAR1; multiple EGF-like domains protein 12; multiple ...... |
Chromosomal Location | 1q23.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting PEAR1 collected from DrugBank database. |
There is no record. |